Regorafenib Suppresses Migration of and Induces Cell Cycle Arrest and Apoptosis in MCF-7 Cells
DOI:
https://doi.org/10.1590/s2175-979020200004181122Keywords:
Regorafenib. MCF-7. Apoptosis. Migration. Cell cycle.Abstract
This study investigated the mechanism underlying the suppression of estrogen receptor-positive MCF7 cell growth by regorafenib. MCF-7 cells were treated with regorafenib, and the effect of regorafenib on multiple cancer-associated pathways was evaluated. Although regorafenib effectively inhibited the proliferation of MCF-7 cells, it had no effect on the proliferation of the normal breast epithelial cell line MCF10A. Regorafenib suppressed MCF-7 cell migration, probably by regulating the homeostatic expression of matrix metalloproteinases and the tissue inhibitor of MMPs. Furthermore, it upregulated p21 expression, downregulated cyclin B1 and cyclin D1 expresssions, and caused cell cycle arrest. In addition, regorafenib induced apoptosis in MCF-7 cells by reducing Mcl-1 expression and activating caspase signaling. These results demonstrate that regorafenib has the potential to be an effective drug for treating breast cancer.
Downloads
References
Bagaria S P, Ray P S, Sim M S, Ye X, Shamonki J M, Cui X, et al. Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg. 2014;149(2):125-9.
Bendris N, Lemmers B and Blanchard J M. Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors. Cell Cycle. 2015;14(12):1786-98.
Caldon CE, Daly R J, Sutherland R L, Musgrove E A. Cell cycle control in breast cancer cells. J Cell Biochem. 2006;97(2):261-74.
Ettrich TJ, Seufferlein T. Regorafenib. Recent Results Cancer Res. 2014;201:185-96.
Groblewska M, Siewko M, Mroczko B, Szmitkowski M. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol. 2012;50(1):12-9.
Inuzuka H, Fukushima H, Shaik S, Liu P, Lau A W, Wei W. Mcl-1 ubiquitination and destruction. Oncotarget. 2011;2(3):239-44.
Jameera Begam A, Jubie S, Nanjan M J. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. Bioorg Chem. 2017;71:257-74.
Labidi S, Mejri N, Lagha A, Daoud N, El Benna H, Afrit M, et al. Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer. Breast Care (Basel). 2016;11(6):418-22.
Lawicki S, Zajkowska M, Glazewska E K, Bedkowska G E, Szmitkowski M. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer. Onco Targets Ther. 2016; 9:911-9.
Mayer E L. Targeting breast cancer with CDK inhibitors. Curr Oncol Rep. 2015;17(5):443.
Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C, et al. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget. 2015;6(29):26560-74.
Quinn B A, Dash R, Azab B, Sarkar S, Das S K, Kumar S, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs. 2011;20(10):1397-411.
Rody A, Cornelia L. Neoadjuvant therapy for patients with triple negative breast cancer (TNBC). Rev Recent Clin Trials. 2017;12(2)73-80.
Saha Roy S, Vadlamudi R K. Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer. 2012;2012:654698.
Santen R J, Yue W and Wang J P. Estrogen metabolites and breast cancer. Steroids. 2015;99(Pt A):61-6.
Santo L, Siu K T, Raje N. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. Semin Oncol. 2015;42(6):788-800.
Sartore-Bianchi A, Siena S, Tonini G, Bardelli A, Santini D. Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. Cancer Treat Rev. 2016;51:54-62.
Schvartsman G, Wagner M J, Zobniw C M, Trinh V A, Patel S, Somaiah N. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Curr Oncol Rep. 2016;18(8):49.
Stalker L, Pemberton J, Moorehead RA. Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors. Cancer Cell Int. 2014,14(1):89.
Thakur V, Bedogni B. The membrane tethered matrix metalloproteinase MT1-MMP at the forefront of melanoma cell invasion and metastasis. Pharmacol Res. 2016;111:17-22.
Thomas L W, Lam C, dwards S W. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010;584(14):2981-9.
Tong J, Tan S, Zou F, Yu J, Zhang L. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene. 2017a;36(6):787-96.
Tong J, Wang P, Tan S, Chen D, Nikolovska-Coleska Z, Zou F, et al. Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells. Cancer Res. 2017b;77(9):2512-21.
Tong J S, Zhang Q H, Wang Z B, Li S, Yang C R, Fu X Q, et al. ER-alpha36, a novel variant of ER-alpha, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCdelta/ERK pathway. PLoS One. 2010;5(11):e15408.
Vilalta M, Rafat M, Graves E E. Effects of radiation on metastasis and tumor cell migration. Cell Mol Life Sci. 2016;73(16):2999-3007.
Weng Z, Luo Y, Yang X, Greenhaw J J, Li H, Xie L, et al. Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis. Toxicology. 2015;327:10-21.
Yamamoto-Ibusuki M, Arnedos M, Andre F. Targeted therapies for ER+/HER2- metastatic breast cancer. BMC Med. 2015;13:137.
Yan Y, Grothey A. Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. Onco Targets Ther. 2015;8:2949-57.
Zoghi B and Elledge R. Endocrine Therapy for Leptomeningeal Metastases from ER-Positive Breast Cancer: Case Report and a Review of the Literature. Breast J. 2016;22(2):218-23.
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
